• To demonstrate that treatment of Invasive Candidiasis/ Candidemia with intravenous (IV) echinocandin followed by oral ibrexafungerp is non-inferior to IV echinocandin followed by oral fluconazole based on Global Response (clinical, radiological and mycological response, as confirmed by the Data Review Committee [DRC]) at Day 14
• To compare the efficacy of the treatment regimens, based on: Global Response at Day 30 and End of Therapy (EOT) as determined by the PI and DRC; Clinical Response as determined by the PI and DRC, Mycological Response as determined by the DRC, no recurrence as determined by the DRC, and fungal-free survival as determined by the DRC.
• To evaluate the safety of the regimens
• To evaluate the pharmacokinetics (PK) of ibrexafungerp All Cause Mortality at Day 30 in the ITT population. - The percentage of subjects with Successful Global Response, as determined by the DRC (based on PI-determined clinical response, mycological response and radiological response [when applicable]) at Day 14.
• The percentage of subjects with Successful Global Response at Day 30 and End of Treatment (EOT) as determined by the PI and the DRC.
• The percentage of subjects with Successful Clinical Response at Day 14 and EOT as determined by the PI and the DRC.
• The percentage of subjects with Successful Mycological Response at Day 14 and EOT as determined by the DRC.
• The percentage of subjects with no recurrence before EOT and at 2 weeks and 6 weeks after EOT as determined by the DRC.
• The percentage of subjects alive with Successful Global Response and no recurrence at 6 weeks after EOT as determined by the DRC.
• Frequency of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), discontinuations due to AEs, serious adverse events (SAEs), and safety laboratory assessments.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: - 99 Years
• Gender: All